Compounded GLP-1 and the 2026 FDA proposal: what patients should know

I’ve had the same conversation a lot this year. Someone asks if compounded weight-loss shots are “banned,” or if they need to stock up, or if a vial from a stranger online is the workaround.

Short answer: the news is real. A lot of the headlines are wrong.

Three clocks people mix up

Clock 1 — shortage. FDA said the national shortages of key GLP-1 injection products were resolved (semaglutide injection: February 2025; tirzepatide earlier). When a shortage ends, the temporary path that let pharmacies compound “essentially copies” of those products ends with it. Local stockouts can still happen. That is not the same as a national shortage listing.

Clock 2 — 503B bulks proposal. On April 30, 2026, FDA proposed keeping semaglutide, tirzepatide, and liraglutide off the 503B bulks list. That list is how large outsourcing facilities compound from bulk ingredients when a product is not on the shortage list. FDA said it did not find a clinical need for that large-scale path when FDA-approved products are available. This is a proposal. Comment period followed. As of early September 2026 it is not a finished “banned forever” rule. Treat absolute ban headlines as marketing until FDA finalizes.

Clock 3 — 503A patient-specific compounding. State-licensed pharmacies can still compound for an identified patient in narrow cases — a documented clinical need the commercial product does not meet (for example, an allergy to an inactive ingredient, or a needed change in form). “Cheaper” is not a clinical difference. “My old telehealth shop ran out” is not, by itself, a clinical difference.

If a site cannot tell you which clock your prescription sits on, ask until they can.

What the April 2026 proposal actually says

It targets the 503B bulk pathway for those three substances. That does not make every compounded product illegal overnight. It also does not green-light unlabeled “research” peptides.

Compounded medicines are not FDA-approved. Say that out loud before you decide anything.

Narrow patient-specific compounding is not the same path

503A is one patient, one prescription, documented reason. 503B is larger-scale outsourcing. Patients, ads, and comment threads smash those together. Don’t.

Your job as a patient is simpler: who evaluated you, what was prescribed, FDA-approved or compounded, which pharmacy, and how you reach that physician after week one.

Safer routes than a gray-market vial

If compounded access shrinks for you, common lawful paths include:

• FDA-approved products through a pharmacy, with insurance if you have it
• Manufacturer cash-pay programs (LillyDirect, NovoCare, and similar) when you already have a valid prescription
• Class-level oral options a physician may consider when they fit — that is a clinical call, not a shopping cart
• A plan to adjust, pause, or switch under physician follow-up — not a cold stop from a stranger’s vial

Gray-market and “research chemical” vials are out. No dosing tips from me on those. Don’t buy them.

How a SensibleDoc membership fits a transition

SensibleDoc is a physician-run lifestyle membership. Founding rate $39/month for physician access (later members $59): messaging, follow-ups, annual basic labs. Medicine, when prescribed, is included or near cost by treatment. Nothing is guaranteed to be approved.

If you are mid-transition — shortage end, pharmacy change, side effects, or “what now” — the useful product is the ongoing physician relationship, not a workaround vendor.

Pricing page. Intake. Physician review. Bring your med list and what you were last on. We’ll sort what is appropriate from what is noise.